CDEK
← All drugs Report issue

etonogestrel

Small moleculeexperimental

Etonogestrel is a medication which is used as a means of birth control for women. It is available as an implant placed under the skin of the upper arm under the brand names Nexplanon and Implanon. It is a progestin that is also used in combination with ethinylestradiol, an estrogen, as a vaginal ring under the brand names NuvaRing and Circlet. Etonogestrel is effective as a means of birth control and lasts at least three or four years with some data showing effectiveness for five years. Following removal, fertility quickly returns. — Wikipedia

Clinical trial activity

27 trials · 46 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
8
Phase 3
3
Phase 4
11

Earliest trial started Jan 31, 2010 (NCT03585504)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • etogestrel

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07201402Phase 2Nov 30, 2025National Institutes of Health (NIH), Yale University
NCT06775626Early Phase 1 (Phase 1)Feb 28, 2025Federal University of Sao Paulo, Organon
NCT06162611Phase 4Nov 6, 2023Planned Parenthood, University of Utah
NCT05994599Phase 1Jul 28, 2023Evestra Inc.
NCT05760144Early Phase 1 (Phase 1)Jul 1, 2023Oregon Health and Science University
NCT05791799Phase 2/Phase 3 (Phase 3)Apr 1, 2023Sun Yat-Sen University
NCT05174884Phase 1Nov 30, 2022Bill and Melinda Gates Foundation, FHI 360
NCT05227456Phase 2Jul 1, 2022Government of Canada, University of Athens, University of Saskatchewan
NCT05360550Phase 2May 27, 2022Lupin
NCT05330871Phase 2Apr 17, 2022People's Liberation Army of China
NCT05237141Phase 4Apr 1, 2022University of Colorado, Denver
NCT05156658Phase 4Feb 25, 2022AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), University of Colorado
NCT05360576Phase 2Feb 24, 2022Lupin
NCT04669678Phase 4Nov 17, 2021Merck, University of Alabama, Birmingham, University of Washington, Wits University
NCT05044962N/AOct 31, 2021AMPATH, Indiana University, Moi Teaching and Referral Hospital, National Institute of Allergy and Infectious Diseases (NIAID), University of Nebraska, University of Washington
NCT04814927Phase 4Mar 1, 2021CONRAD, Eastern Virginia Medical School, Kenya Medical Research Institute, United States Agency for International Development
NCT04423068Early Phase 1 (Phase 1)Jan 1, 2021University of Kansas
NCT04626596Phase 3Nov 19, 2020Merck
NCT04463693Phase 4Oct 14, 2020University of Colorado, Denver
NCT04423055Phase 4Jul 31, 2020Merck, University of California, Davis, University of Colorado, Denver, University of Pennsylvania
Showing 20 of 27 trials
Page 1 / 2

Organizations

Research & Development (46)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit4122012
University of Colorado, DenverAcademic/Hospital3212020
LupinFor profit2212022
National Institute of Allergy and Infectious Diseases (NIAID)Government2022021
University of NebraskaAcademic/Hospital2022018
University of PennsylvaniaAcademic/Hospital2112020
University of WashingtonAcademic/Hospital2222021
AIDS Clinical Trials GroupAcademic/Hospital1112022
American College of Obstetricians and GynecologistsAcademic/Hospital1012010
AMPATHAcademic/Hospital1012021
Assiut UniversityAcademic/Hospital1112018
BayerFor profit1012010
Bill and Melinda Gates FoundationAcademic/Hospital1012022
Chulalongkorn UniversityAcademic/Hospital1112018
clinique ovoAcademic/Hospital1112012
CONRADFor profit1012021
Eastern Virginia Medical SchoolAcademic/Hospital1112021
Evestra Inc.For profit1112023
Federal University of Sao PauloAcademic/Hospital1112025
FHI 360Academic/Hospital1112022
46 organizations
Page 1 / 3